Levesque et al. recently reported the improvement of peptide-based specific PACE4 inhibitors for treatment of prostate cancer [44, 45] and Zhu et al. described the first furin-specific inhibitory nanobodies [30]. This evidence concerns the gene PCSK6 and prostate carcinoma.